Press Release FeedGet the RSS feed
Menu

GlobeNewswire

Global Cell Culture Media and Single-Use Reagents Market Report 2026 | Capitalize on 13.6% CAGR to $8.34B by 2030 with Thermo Fisher, Merck, Sartorius and Lonza

Thermo Fisher Scientific Inc.

Dublin, Oct. 21, 2026 -- "Cell Culture Media and Single-Use Reagents Market Report 2026" has been added to ResearchAndMarkets.com's offering.

Cell Culture Media and Single-Use Reagents Market Poised to Reach $8.34 Billion by 2030

The global cell culture media and single-use reagents market is experiencing rapid expansion, supported by rising biopharmaceutical production, increased investment in advanced therapies, and wider adoption of disposable bioprocessing technologies. The market is projected to grow from $4.41 billion in 2025 to $5.00 billion in 2026, representing a compound annual growth rate (CAGR) of 13.4%.

Historical market growth has been influenced by the adoption of serum-based cell culture systems, the gradual transition from reusable laboratory consumables, and early-stage implementation of single-use technologies. Market development has also reflected the limited availability of standardized Good Manufacturing Practice (GMP)-grade reagents and the fragmented nature of global bioprocessing supply chains.

Looking ahead, the cell culture media and single-use reagents market is forecast to reach $8.34 billion by 2030, expanding at a CAGR of 13.6%. Key growth drivers include the shift toward serum-free and chemically defined media, expansion of large-scale biomanufacturing facilities, and growing demand for cell and gene therapy production. Increased investment in automated and high-throughput cell culture platforms is also expected to support market growth through the forecast period.

Prominent cell culture media market trends include the increased use of serum-free formulations, expansion of single-use bioprocessing systems, and rising demand for contamination-controlled aseptic manufacturing. Biopharmaceutical companies are also placing greater emphasis on regulatory-compliant GMP-grade reagents, high-throughput screening platforms, scalable production processes, and consistent batch performance.

Growing investment in cell and gene therapy development is a major factor accelerating demand for cell culture media and single-use reagents. The increasing prevalence of genetic and rare diseases is encouraging public and private organizations to direct more capital toward advanced therapy research, clinical development, and commercial manufacturing. Cell culture products and disposable reagents support sterile, scalable, and efficient production workflows for these therapies.

Investment figures highlight the continued momentum within the advanced therapies sector. According to the UK-based Cell and Gene Therapy Catapult, total investment in advanced therapies reached £0.77 billion in 2023 and increased to £0.97 billion in 2024. This represented year-on-year growth of 26%, demonstrating sustained commercial interest in cell and gene therapy technologies and the manufacturing infrastructure required to support them.

Product innovation remains central to competition in the cell culture media and single-use reagents market. Manufacturers are developing integrated single-use bioreactor systems designed to improve production efficiency, simplify setup, accelerate changeovers, and reduce contamination risks. These platforms are increasingly important for process intensification and the scalable manufacture of biologics, vaccines, and advanced therapies.

In August 2023, Sartorius AG and Repligen Corporation launched an integrated Biostat STR system featuring XCell ATF technology. The system incorporates cell-retention capabilities and predefined control recipes to support intensified bioprocessing while reducing setup complexity. Faster installation, a more efficient equipment footprint, and improved scalability can help biomanufacturers lower operating costs and increase productivity in commercial cell culture operations.

Strategic acquisitions are also reshaping the competitive landscape. In August 2024, Merck KGaA acquired Mirus Bio for $600 million. The transaction strengthened Merck's cell culture and gene delivery portfolio, particularly in transfection reagents used across biologics, vaccine development, and cell and gene therapy workflows. The acquisition reflects growing demand for integrated technologies that support genetic material delivery and advanced biopharmaceutical manufacturing.

North America was the largest region in the cell culture media and single-use reagents market in 2025, supported by its established biopharmaceutical sector, advanced research infrastructure, and strong investment in cell and gene therapies. Asia-Pacific is expected to be the fastest-growing region during the forecast period. Market coverage includes Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, with analysis spanning Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy, and Spain.

Markets Covered:
1) By Cell Type: Mammalian Cells; Stem Cells; Insect Cells; Microbial Cells; Plant Cells
2) By Technology: Single-Use Bioprocessing Systems; Continuous Bioprocessing; Upstream Processing Technologies; Downstream Processing Technologies
3) By Portability And Scale: Fully Automated Benchtop Systems; Portable And Handheld Analyzers; Fully Integrated Core-Lab Systems
4) By Application: Biopharmaceutical Production; Vaccine Manufacturing; Gene Therapy; Cell Therapy; Cell Culture Research

Subsegments:
1) By Mammalian Cells: Chinese Hamster Ovary Cells; Human Embryonic Kidney Cells; Baby Hamster Kidney Cells; Mouse Myeloma Cells; Hybridoma Cells
2) By Stem Cells: Embryonic Stem Cells; Adult Stem Cells; Induced Pluripotent Stem Cells; Mesenchymal Stem Cells; Hematopoietic Stem Cells
3) By Insect Cells: Spodoptera Frugiperda Cells; Trichoplusia Ni Cells; Drosophila Melanogaster Cells
4) By Microbial Cells: Escherichia Coli Cells; Saccharomyces Cerevisiae Cells; Pichia Pastoris Cells; Bacillus Subtilis Cells
5) By Plant Cells: Tobacco Plant Cells; Rice Plant Cells; Carrot Plant Cells; Arabidopsis Thaliana Cells

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Key Attributes:

Report AttributeDetails
No. of Pages250
Forecast Period2026 - 2030
Estimated Market Value (USD) in 2026$5 Billion
Forecasted Market Value (USD) by 2030$8.34 Billion
Compound Annual Growth Rate13.6%
Regions CoveredGlobal

Companies Featured

The companies featured in this Cell Culture Media and Single-Use Reagents market report include:

  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Fujifilm Wako
  • Corning Incorporated
  • Lonza Group AG
  • Avantor Inc.
  • Agilent Technologies
  • Sartorius AG
  • Bio-Rad Laboratories Inc.
  • Bio-Techne Corporation
  • STEMCELL Technologies
  • Miltenyi Biotec
  • LGC Science Group Holdings Ltd
  • Takara Bio Inc.
  • MP Biomedicals LLC
  • Chemglass Life Sciences
  • ATCC
  • ITW Reagents
  • PromoCell GmbH
  • Axol Bioscience Ltd
  • HiMedia Laboratories
  • Eppendorf AG
  • Kohjin Bio Co. Ltd.
  • Nucleus Biologics
  • OPM Biosciences
  • Plant Cell Technology
  • ZenBio Inc.
  • Yocon Corporation.

For more information about this report visit https://www.researchandmarkets.com/r/q6nqb

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  1. AIGlobal Bioprocessing Reagent Market Report 2026 | Capitalize on 12.3% CAGR as Thermo Fisher, Danaher, Merck KGaA and Sartorius Accelerate AI and Single-Use SystemsCompanies: Thermo Fisher Scientific Inc.Danaher CorporationMerck KGaABoost ROI via single-use systems, AI optimization and continuous processing to cut capital costs, contamination and downtime while improving yield, scalability and efficiency.
  2. Biotech & pharmaGlobal Bioprocessing Support Services Market Report 2026 | Capitalize on $4.13B by 2030 as Thermo Fisher, Merck, Sartorius and Samsung Biologics Scale Single-Use SolutionsCompanies: Thermo Fisher Scientific Inc.Boost ROI by outsourcing services, adopting single-use integrated platforms, and standardizing scale-up, optimization and compliance to cut costs and speed production.
  3. Upstream Bioprocessing Equipment Market Report 2026: Forecast to 2030 | Accelerate Single-Use Scale-Up as Thermo Fisher, Merck, Danaher, Sartorius and Repligen Drive 10.9% CAGRCompanies: Thermo Fisher Scientific Inc.Danaher Corporation"Upstream Bioprocessing Equipment Market Report 2026" has been added to ResearchAndMarkets.com's offering.
  4. Biotech & pharmaBioconjugation Market Report 2026: Global Size, Share, Trends and 2030 Forecast | Capitalize on Targeted Therapeutics | Thermo Fisher, Merck, Danaher, Lonza, and Agilent Lead the IndustryCompanies: Thermo Fisher Scientific Inc.Agilent TechnologiesDanaher Corporation"Bioconjugation Market Report 2026" has been added to ResearchAndMarkets.com's offering.
  5. Cell-Based Biological Reagents Global Market Report 2026-2030 | Capitalize on 8.6% CAGR | Thermo Fisher, Merck, Danaher and Lonza Lead the IndustryCompanies: Thermo Fisher Scientific Inc.Danaher Corporation"Cell-based Biological Reagents Market Report 2026" has been added to ResearchAndMarkets.com's offering.
  6. FinanceGlobal Human Osteoblasts Market Report 2026 | Capitalize on $53.09 Billion Revenue Share by 2030 as Merck KGaA, Thermo Fisher Scientific, Lonza and STEMCELL Lead the IndustryCompanies: Merck KGaAThermo Fisher Scientific Inc."Human Osteoblasts Market Report 2026" has been added to ResearchAndMarkets.com's offering.